Tian-Jun Jiang
Overview
Explore the profile of Tian-Jun Jiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li B, Fan X, Cao W, Tian H, Wang S, Zhang J, et al.
Infect Dis Immun
. 2024 Apr;
1(2):74-85.
PMID: 38630120
Background: The ongoing global coronavirus disease 2019 (COVID-19) pandemic is posing a serious public health threat to nations worldwide. Understanding the pathogenesis of the disease and host immune responses will...
2.
Shi Y, Huang H, Wang X, Song B, Jiang T, Yu M, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256948
(1) Background: The objective of this study was to investigate the prevalence of genetic diversity and drug resistance mutations among people living with HIV (PLWH) attending clinics in Beijing. (2)...
3.
Xia P, Xing X, Yang C, Liao X, Liu F, Huang H, et al.
Mil Med Res
. 2022 May;
9(1):24.
PMID: 35619176
Background: Mucosal-associated invariant T (MAIT) cells are systemically depleted in human immunodeficiency virus type 1 (HIV-1) infected patients and are not replenished even after successful combined antiretroviral therapy (cART). This...
4.
Wang X, Zhang J, Xing X, Huang H, Xia P, Dai X, et al.
Cell Discov
. 2022 Mar;
8(1):29.
PMID: 35351857
To obtain a comprehensive scenario of T cell profiles and synergistic immune responses, we performed single-cell RNA sequencing (scRNA-seq) on the peripheral T cells of 14 individuals with chronic human...
5.
Xu R, Zhang J, Tu B, Xu Z, Huang H, Huang L, et al.
Signal Transduct Target Ther
. 2021 May;
6(1):174.
PMID: 33958574
Severely immunosuppressed AIDS patients with recurrent opportunistic infections (OIs) represent an unmet medical need even in the era of antiretroviral therapy (ART). Here we report the development of a human...
6.
Yang P, Ding Y, Xu Z, Pu R, Li P, Yan J, et al.
Infect Dis Poverty
. 2020 Nov;
9(1):161.
PMID: 33239109
Background: Coronavirus disease 2019 (COVID-19) is pandemic. It is critical to identify COVID-19 patients who are most likely to develop a severe disease. This study was designed to determine the...
7.
Zhang J, Wang X, Xing X, Xu Z, Zhang C, Song J, et al.
Nat Immunol
. 2020 Aug;
21(9):1107-1118.
PMID: 32788748
In coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity and the host immune response is not fully understood. Here...
8.
Wang J, Wang Z, Jing J, Zhao P, Dong J, Zhou Y, et al.
Chin J Integr Med
. 2020 Jul;
26(9):648-655.
PMID: 32676976
Objectives: To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients. Methods: A putative ARDS-suppressing...
9.
Song J, Zhang C, Fan X, Meng F, Xu Z, Xia P, et al.
Nat Commun
. 2020 Jul;
11(1):3410.
PMID: 32641700
COVID-19 is associated with 5.1% mortality. Although the virological, epidemiological, clinical, and management outcome features of COVID-19 patients have been defined rapidly, the inflammatory and immune profiles require definition as...
10.
Song J, Lam S, Fan X, Cao W, Wang S, Tian H, et al.
Cell Metab
. 2020 Jul;
32(2):188-202.e5.
PMID: 32610096
The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented threat to global public health. Herein, we utilized a combination of targeted and untargeted tandem mass spectrometry to analyze the plasma...